Connect with us

Pain

Study demonstrates significant improvement in pain from CBD

The studies have been selected for presentation at the IACM Conference on Cannabinoids in Medicine, Basel 2022.

Published

on

Study demonstrates significant improvement in pain from CBD
Home » Health » Pain » Study demonstrates significant improvement in pain from CBD

Three peer-reviewed pre-clinical studies and one clinical study have been selected to be presented at the IACM conference which explore the benefits of CBD.

The clinical research focuses on the delivery of a CBD preparation to patients with Vestibulodynia (VBD), which is a prevalent form of chronic genital pain in women with no standard treatment. 

The randomised placebo control study of 60 patients showed significant improvement of outcomes on pain, dyspareunia (genital pain before, during or after sex), pelvic muscular tone and neurometer parameters, which highlights implications for its anti-inflammatory, anti-nociceptive action and anti-neuropathic therapeutic potential. 

Read more: Promise for CBD as treatment for post-operative pain

The preclinical research that will be presented focuses on the potential positive impact of CBD on the treatment of several psychiatric disorders and inflammatory disease, the therapeutic potential for migraine pain and trigeminal excitability related to migraine.

The papers will be presented by chief scientific officer of Curaleaf Holdings , Dr Barbara Pacchetti Curaleaf Holdings, and will be published in the official Conference Proceedings Journal Medical Cannabis and Cannabinoids.

Pacchetti commented: “We are very pleased with the findings from our clinical study on the delivery of CBD to treat patients with VBD, and that it is showing a significant improvement in pain outcomes for patients. 

“Additionally, the preclinical research on the therapeutic potential of CBD to treat a number of other indications is also encouraging and I look forward to presenting this to the scientific community and to furthering our research into the potential for CBD. 

“We believe the growth and understanding of medical cannabis must be underpinned by the most robust science. 

“Curaleaf International is working with some of the world’s leading academic institutions such as Imperial College, the University of Milan and University of Insubria and we look forward to further updating all stakeholders with our progress.”

[activecampaign form=33]

Stephanie is the editor of Cannabis Wealth and Psychedelic Health, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine 'Game Theory' focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. After working for a number of years as a local journalist, Stephanie became the editor of two publications covering health and wellness, including psychedelics and global developments in cannabis, before joining the team at Aspect publishing. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on "Medical Cannabis Explained". Contact: stephanie@handwmedia.co.uk

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.